Patient group
Erwachsene Patienten mit chronischer Immunthrombozytopenie, die refraktär gegenüber anderen Behandlungen sind
completed2020-07-01D series
Fostamatinib
Chronische Immunthrombozytopenie
Open official case page ↗
- Brand
- Tavlesse®
- Manufacturer
- Grifols Deutschland GmbH
G-BA action
final resolution
2020-12-17
Arzneimittel-Richtlinie/Anlage XII: Fostamatinib (Chronische Immunthrombozytopenie)
Evidence-checked summary
The G-BA found no proven added benefit for Erwachsene Patienten mit chronischer Immunthrombozytopenie, die refraktär gegenüber anderen Behandlungen sind. The appropriate comparator was Eltrombopag oder Romiplostim. The G-BA issued a final resolution on 2020-12-17. The official page states that it took effect as follows: 17.12.2020. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2020-11-09
65 parsed turns
Oral hearing: Fostamatinib (Chronische Immunthrombozytopenie)
Official Wortprotokoll · 13 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A20-53
matched
Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 31 pages
G-BA decisions
Distinct actions and documents
2020-12-17
final resolution
Arzneimittel-Richtlinie/Anlage XII: Fostamatinib (Chronische Immunthrombozytopenie)
The G-BA found no proven added benefit for Erwachsene Patienten mit chronischer Immunthrombozytopenie, die refraktär gegenüber anderen Behandlungen sind. The appropriate comparator was Eltrombopag oder Romiplostim. The G-BA issued a final resolution on 2020-12-17. The official page states that it took effect as follows: 17.12.2020. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗annex xii current versionFostamatinibOpen ↗comparator informationInformationen zur zweckmäßigen VergleichstherapieOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗iqwig assessmentNutzenbewertung IQWiGOpen ↗